Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncopeptides AB ( (SE:ONCO) ) just unveiled an announcement.
Oncopeptides AB, a Stockholm-listed biotech focused on targeted cancer treatments, leverages its proprietary PDC and SPiKE platforms to develop drugs that selectively deliver cytotoxic agents into tumor cells. Its lead product Pepaxti is gaining commercial traction in Europe, underpinned by regional partnership deals and a growing operational footprint across several key EU markets.
The company has published its 2025 annual report, highlighting a strategic shift from a launch phase toward a growth and scientific validation stage driven by strong triple-digit growth in Pepaxti. Management underscores the potential to extend the validated PDC platform into new, high-value indications, signaling an ambition to broaden the pipeline and strengthen Oncopeptides’ competitive position in the oncology market.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotech company specializing in targeted therapies for difficult-to-treat cancers, built on its proprietary Peptide Drug Candidate and SPiKE technology platforms. The company’s flagship cancer drug, Pepaxti, is being commercialized in Europe, supported by partnership agreements in South Korea, the Middle East, Africa and other regions, and it operates with about 80 employees across Sweden, Germany, Austria, Spain and Italy.
Average Trading Volume: 2,896,004
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK518.2M
Learn more about ONCO stock on TipRanks’ Stock Analysis page.